If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
Portfolio Pulse from Shanthi Rexaline
Vivek Ramaswamy, a Republican presidential candidate and founder of Roivant Sciences, Inc. (NASDAQ:ROIV), has seen his company's stock rise since announcing his candidacy. A $1,000 investment in Roivant when Ramaswamy announced his candidacy would have yielded a 30% return in six months. This compares to a 9.5% gain by the S&P 500 Index and a nearly 6% drop by the SPDR S&P Biotech ETF (NYSE:XBI). Roivant's subsidiaries include publicly listed Immunovant, Inc. (NASDAQ:IMVT).
August 25, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The SPDR S&P Biotech ETF (NYSE:XBI) has seen a nearly 6% drop in the same six-month timeframe.
The news indirectly compares the performance of the SPDR S&P Biotech ETF to that of Roivant Sciences, highlighting the ETF's recent drop.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Immunovant, Inc. is a publicly listed subsidiary of Roivant Sciences.
While Immunovant is a subsidiary of Roivant, the news does not directly impact the company's stock price.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Roivant Sciences' stock has risen since founder Vivek Ramaswamy announced his presidential candidacy.
The news of Ramaswamy's presidential candidacy has likely increased investor interest in Roivant, leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100